Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP

Journal of Cellular Biochemistry

Volumn 112, Issue 2, 2011, Pages 509-519

  Wang, Jia ^a   Zhao, Qing ^a   Qi, Qi ^a   Gu, Hong Yan ^a   Rong, Jing Jing ^a   Mu, Rong ^a   Zou, Mei Juan ^a   Tao, Lei ^a   You, Qi Dong ^a   Guo, Qing Long ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

chaperone; chip; gambogic acid; mutant P53; proteasome

Indexed keywords

CHAPERONE; CYCLOHEXIMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GAMBOGIC ACID; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESSENGER RNA; MUTANT PROTEIN; PROTEASOME; PROTEIN CHIP; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; COMPLEX FORMATION; CYTOTOXICITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOHEXIMIDE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; MICE, NUDE; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79251631447     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22941     Document Type: Article

References (48)

1. Barrett AJ,. 1992. Cellular proteolysis. An overview. Ann N Y Acad Sci 674: 1-15.
2. Blandino G, Levine AJ, Oren M,. 1999. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485.
3. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A,. 2006. Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25: 304-309.
4. Buschmann T, Minamoto T, Wagle N, Fuchs SY, Adler V, Mai M, Ronai Z,. 2000. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. J Mol Biol 295: 1009-1021.
5. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P,. 2000. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 18: 1465-1473.
6. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, Dixit VM,. 2004. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-92.
7. Esser C, Scheffner M, Hohfeld J,. 2005. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 280: 27443-27448.
8. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ,. 1988. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539.
9. Freedman DA, Levine AJ,. 1999. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 59: 1-7.
10. Freedman DA, Wu L, Levine AJ,. 1999. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107.
11. Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, Mu R, Yang Y, Qi Q, Liu W, Lu N, Ling H, You Q, Guo Q,. 2008. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther 7: 3298-3305.
12. Gu H, Rao S, Zhao J, Wang J, Mu R, Rong J, Tao L, Qi Q, You Q, Guo Q,. 2009. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 135: 1777-1782.
13. Hainaut P, Hollstein M,. 2000. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 77: 81-137.
14. Haupt Y, Maya R, Kazaz A, Oren M,. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
15. Jayaraman L, Prives C,. 1999. Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 55: 76-87.
16. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J, Patterson C,. 2001. CHIP is a U-box-dependent E3 ubiquitin ligase: Identification of Hsc70 as a target for ubiquitylation. J Biol Chem 276: 42938-42944.
17. Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, Jiang S, Zhang HZ, Gehlsen KR, Cai SX, Green DR, Tseng B,. 2005. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 102: 12095-12100.
18. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S,. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
19. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G,. 2000. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97: 4174-4179.
20. Lu N, Yang Y, You QD, Ling Y, Gao Y, Gu HY, Zhao L, Wang XT, Guo QL,. 2007. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett 258: 80-89.
21. Lukashchuk N, Vousden KH,. 2007. Ubiquitination and degradation of mutant p53. Mol Cell Biol 27: 8284-8295.
22. Magnani M,. 2000. Ubiquitin/proteasome system. Nat Biotechnol 18: 807.
23. Melchior F, Hengst L,. 2002. SUMO-1 and p53. Cell Cycle 1: 245-249.
24. Milner J, Medcalf EA,. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765-774.
25. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B,. 2008. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 27: 3371-3383.
26. Murata S, Minami Y, Minami M, Chiba T, Tanaka K,. 2001. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep 2: 1133-1138.
27. Nagata Y, Anan T, Yoshida T, Mizukami T, Taya Y, Fujiwara T, Kato H, Saya H, Nakao M,. 1999. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 association. Oncogene 18: 6037-6049.
28. Peng Y, Chen L, Li C, Lu W, Chen J,. 2001. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276: 40583-40590.
29. Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM,. 2002. Novel gain of function activity of p53 mutants: Activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 21: 4595-4600.
30. Qi Q, Gu H, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang X, Guo Q,. 2008. Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med 86: 1367-1377.
31. Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, Zhang X, Ding J,. 2007. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 6: 2429-2440.
32. Rajendra R, Malegaonkar D, Pungaliya P, Marshall H, Rasheed Z, Brownell J, Liu LF, Lutzker S, Saleem A, Rubin EH,. 2004. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem 279: 36440-36444.
33. Rong JJ, Hu R, Qi Q, Gu HY, Zhao Q, Wang J, Mu R, You QD, Guo QL,. 2009. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett 284: 102-112.
34. Roth JA, Cristiano RJ,. 1997. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 89: 21-39.
35. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G,. 2007. Mutant p53: An oncogenic transcription factor. Oncogene 26: 2212-2219.
36. Sun Y, Nakamura K, Wendel E, Colburn N,. 1993. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci USA 90: 2827-2831.
37. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X,. 2006. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 8: 855-862.
38. Tsang WP, Ho FY, Fung KP, Kong SK, Kwok TT,. 2005. p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer 114: 331-336.
39. Vogelstein B, Lane D, Levine AJ,. 2000. Surfing the p53 network. Nature 408: 307-310.
40. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L,. 1997. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14: 2809-2816.
41. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH,. 1998. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18: 1517-1524.
42. Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT,. 2007. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther 6: 1054-1061.
43. Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, Bae E, Toriyama S, Ikeda R, Zhang L, Fujitani K, Yoo E, Tsuchimochi K, Ohta T, Araya N, Fujita H, Aratani S, Eguchi K, Komiya S, Maruyama I, Higashi N, Sato M, Senoo H, Ochi T, Yokoyama S, Amano T, Kim J, Gay S, Fukamizu A, Nishioka K, Tanaka K, Nakajima T,. 2007. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J 26: 113-122.
44. Yang Y, Yang L, You QD, Nie FF, Gu HY, Zhao L, Wang XT, Guo QL,. 2007. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett 256: 259-266.
45. Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X,. 2007. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28: 632-638.
46. Zambetti GP, Levine AJ,. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865.
47. Zhang HZ, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, Drewe J, Cai SX,. 2004. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 12: 309-317.
48. Zhao Q, Yang Y, Yu J, You QD, Zeng S, Gu HY, Lu N, Qi Q, Liu W, Wang XT, Guo QL,. 2008. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells. Cancer Lett 262: 223-231.